Junzhi
JUNZHI Biomedical is a Taiwanese biotech team dedicated to preventive healthcare. They provide convenient and precise testing solutions, focusing on early detection of cancers, especially gastrointestinal cancers, through advanced SAA protein testing technology. Their mission is to promote health and early diagnosis, leveraging cutting-edge research and international collaborations.
Industries
Nr. of Employees
small (1-50)
Products
SAA蛋白質檢測
血清澱粉樣蛋白A (SAA) 蛋白質檢測是一種僅需3分鐘抽血即可進行的血液篩檢服務，用於多種消化系統癌症的早期風險評估與篩檢。
SAA血清澱粉樣蛋白A癌症檢驗
運用磁性奈米粒子技術純化分離血液中微量的SAA，並透過MALDI-TOF MS質譜儀分析技術解析SAA異構體，結合AI數據分析有效區分癌症和非癌症的精準檢驗服務。
消化系統SAA蛋白質奈米質譜檢測方案
A serum-based SAA protein nanomass spectrometry detection solution for early gastrointestinal cancer screening targeting colorectal and gastric cancers.
SAA蛋白質檢測
血清澱粉樣蛋白A (SAA) 蛋白質檢測是一種僅需3分鐘抽血即可進行的血液篩檢服務，用於多種消化系統癌症的早期風險評估與篩檢。
SAA血清澱粉樣蛋白A癌症檢驗
運用磁性奈米粒子技術純化分離血液中微量的SAA，並透過MALDI-TOF MS質譜儀分析技術解析SAA異構體，結合AI數據分析有效區分癌症和非癌症的精準檢驗服務。
消化系統SAA蛋白質奈米質譜檢測方案
A serum-based SAA protein nanomass spectrometry detection solution for early gastrointestinal cancer screening targeting colorectal and gastric cancers.
Services
Clinical laboratory service that analyzes serum SAA isoform patterns from a single blood draw to assess risk for gastric and colorectal cancer. Workflow includes magnetic nanoparticle enrichment, MALDI-TOF MS profiling, AI-based data analysis, and a diagnostic report provided to the ordering clinician or patient.
Laboratory services including nanoparticle-based sample purification, mass spectrometry analysis, data processing, and generation of clinical reports for biomarker screening assays.
Collaborative R&D and licensing arrangements with academic partners and industry to develop, validate, and internationalize nanoparticle-assisted mass-spectrometry diagnostic platforms.
Clinical laboratory service that analyzes serum SAA isoform patterns from a single blood draw to assess risk for gastric and colorectal cancer. Workflow includes magnetic nanoparticle enrichment, MALDI-TOF MS profiling, AI-based data analysis, and a diagnostic report provided to the ordering clinician or patient.
Laboratory services including nanoparticle-based sample purification, mass spectrometry analysis, data processing, and generation of clinical reports for biomarker screening assays.
Collaborative R&D and licensing arrangements with academic partners and industry to develop, validate, and internationalize nanoparticle-assisted mass-spectrometry diagnostic platforms.
Expertise Areas
- Biomarker discovery and validation
- Proteomics and mass spectrometry
- Nanoparticle-based sample enrichment
- AI-driven diagnostic algorithm development
Key Technologies
- MALDI-TOF mass spectrometry
- Magnetic nanoparticle immunoaffinity enrichment
- Antibody-conjugated nanoprobes
- Isoform-resolved proteomics
News & Updates
JUNZHI Biomedical signed an MOU with the University of South Australia to promote the global development of nanomass spectrometry technology.
JUNZHI Biomedical is part of a cancer alliance involving five hospitals and industry partners to combat cancer.
JUNZHI Biomedical showcased their innovative cancer detection technology at the medical tech exhibition.
JUNZHI Biomedical introduced their SAA protein testing as a new era in precision medicine and health management.
The SAA test received approval for self-paying codes in Hsinchu County, Taiwan.
The collaboration aims to advance the internationalization of nanomass spectrometry platform technology.
JUNZHI Biomedical signed an MOU with the University of South Australia to promote the global development of nanomass spectrometry technology.
JUNZHI Biomedical is part of a cancer alliance involving five hospitals and industry partners to combat cancer.
JUNZHI Biomedical showcased their innovative cancer detection technology at the medical tech exhibition.
JUNZHI Biomedical introduced their SAA protein testing as a new era in precision medicine and health management.
The SAA test received approval for self-paying codes in Hsinchu County, Taiwan.
The collaboration aims to advance the internationalization of nanomass spectrometry platform technology.